Doxepin Hydrochloride Capsule
FDA Label NDC 69238-1166

41 label sections · Submitted to the FDA by Amneal Pharmaceuticals Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Amneal Pharmaceuticals Llc for the product Doxepin Hydrochloride (NDC 69238-1166). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: suicidal thoughts and behaviors, 1 indications and usage, 2.1 screen for bipolar disorder prior to starting doxepin hydrochloride capsules, 2.2 recommended dosage, 2.3 switching patients to or from a monoamine oxidase inhibitor, 2.4 dosage modifications intended to reduce the risk of anticholinergic effects, 2.5 dosage modifications for strong cyp2d6 inhibitors, 2.6 dosage modifications in known cyp2d6 and cyp2c19 poor metabolizers, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

* Please review the disclaimer below.